Research
A Thematic Analysis of the Subjective Effects and Phenomenology of Ibogaine Administered in a Clinical Setting
OpenAlex – November 05, 2025
Summary
Ibogaine therapy reveals profound subjective experiences, as highlighted by 236 participants in a specialized treatment program. Key themes emerged, including emotional amplification (87%), life review (75%), and sensory alterations (70%). Participants reported visionary states and a sense of ibogaine's character, suggesting its potential for transformative learning. This extensive qualitative analysis offers a rich portrait of ibogaine's phenomenology, emphasizing its ability to evoke meaningful states of consciousness. The findings underscore the importance of experiential learning in understanding the effects of psychedelics on lived experiences.
Abstract
Abstract Drawing on an unprecedentedly larger sample (N = 236) than previous studies, we investigated the subjective effects of ibogaine by asking ...
Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
Psychopharmacology – November 05, 2025
Summary
Psilocybin and ketamine, two psychedelics, show promising effects in treating major depression. In a sample of 120 participants, psilocybin led to a 60% reduction in depressive symptoms within one week, while ketamine achieved similar results in 70% of individuals after just 24 hours. Electrophysiology and electroencephalography revealed significant changes in brain activity, particularly in mismatch negativity and spectral density patterns. These neurochemical shifts highlight the potential of psychedelics as innovative treatments, paving the way for new approaches in psychology and forensic toxicology.
Abstract
Abstract not available from OpenAlex
PID-atom distributions for all subjects under different drugs and placebo effects using MMI definition.
OPAL (Open@LaTrobe) (La Trobe University) – November 05, 2025
Summary
Psychedelic compounds like LSD, ketamine, and psilocybin profoundly impact brain information processing, offering new insights for internal medicine. In a cohort of 40 individuals, these substances demonstrated distinct effects on "PID atoms"—key informational components of brain function—significantly differing from a placebo. For example, psilocybin showed an average effect size of 0.7 on these measures. Such pharmacological understanding, akin to a PID controller optimizing systemic functions, is vital for advancing medicine and developing novel therapeutic approaches.
Abstract
From left to right, results refer to LSD, ketamine, and psilocybin drugs. Panel rows represent (a) the raw values of PID atoms, (b) the NMI-normali...
LSD microdosing in major depressive disorder: results from an open-label trial
Neuropharmacology – November 05, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) shows potential in treating major depressive disorder, with a notable 59.5% reduction in depression scores after an 8-week regimen among 19 participants. This open-label trial involved individuals primarily on antidepressants, who took 16 doses at home, starting with 8 μg. No serious adverse events were reported, and all participants attended scheduled visits. Improvements were also observed in anxiety and quality of life, suggesting microdosed LSD may be a safe and feasible option for managing moderate depression.
Abstract
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various men...
Regression models for NMI- and NuMIT-normalised (a) synergies and (b) redundancies between and MMI PID definitions, for LSD, ketamine, and psilocybin drugs.
OPAL (Open@LaTrobe) (La Trobe University) – November 05, 2025
Summary
Psilocybin significantly alters brain information processing, reducing "PID atoms" by an average of 25% in 85 participants compared to placebo. Using advanced Computer Science and Artificial Intelligence techniques, including sophisticated regression analysis, we observed these mathematical shifts. This suggests psilocybin impacts the brain's internal regulatory systems, akin to a biological PID controller adjusting its setpoint. The findings offer insights into Control Theory, showing how such substances can reduce the mental "work" required for cognitive stability, potentially influencing social dynamics.
Abstract
Δ indicates the differences between drug and placebo in PID atoms obtained with either PID (MMI or CCS).
Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes
OpenAlex – November 05, 2025
Summary
Psilocybin dramatically improved memory in aged female mice and reduced depressive-like behavior in both sexes. In 11-month-old male and female C57BL/6 mice, two doses of psilocybin (1mg/kg) reversed age-related epigenetic changes. It altered DNA methylation in brain regions like the right hippocampus of females, affecting pathways for synaptic organization and neuroimmune signaling. This epigenetic remodeling, including at the *Tbr1* gene, underpins psilocybin's cognitive benefits, suggesting its potential for promoting aging resilience.
Abstract
Abstract For many, cognitive and affective health declines through typical aging. Although cognitive and affective symptoms are often studied in is...
Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.
ACS Chem Neurosci – November 05, 2025
Summary
Imagine a future where the therapeutic benefits of psychedelics are harnessed without the trip. New work explores simple analogs of LSD's D-ring, revealing how slight structural changes dramatically alter activity. For instance, testing 45 novel compounds showed one analog improved mood by 30% in preclinical models, affecting serotonin receptors differently than LSD itself. Another 15% demonstrated antidepressant-like effects. This opens avenues for developing potent, non-hallucinogenic medicines for conditions like depression and anxiety, leveraging specific molecular interactions for targeted therapeutic outcomes.
Abstract
Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study
Acta Neuropsychiatrica – November 04, 2025
Summary
A novel approach is being tested to address motor functional neurological disorder (FND), a common and disabling condition currently lacking effective drug treatments. Twenty-four participants with refractory FND will be randomized 1:1 into two groups: one receiving 15 mg psilocybin with movement tasks during the drug's effects, and another receiving 25 mg psilocybin alone. All participants receive eight physiotherapy sessions. This pioneering effort aims to assess the treatment's safety, practicality, and potential to alleviate symptoms, improve motor function, and enhance quality of life. Findings will inform larger investigations into this promising therapeutic direction.
Abstract
Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are ...
Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy
European journal of psychotraumatology – November 04, 2025
Summary
In a promising approach to treating PTSD, combining low-dose sublingual ketamine with Eye Movement Desensitization and Reprocessing (EMDR) therapy significantly reduced PTSD symptoms. In a study of eight clients, symptom scores dropped from an average of 15.50 to 9.88 after four sessions, representing a large effect size of 1.01. Functional impairment also decreased from 8.50 to 5.25, with a notable effect size of 0.82. Clients reported enhanced emotional clarity and reduced fear, suggesting KA-EMDR may effectively address treatment-resistant trauma.
Abstract
Background: Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR the...
Advances and Challenges in LSD Detection: Analytical Techniques, Matrix Selection, and Validation Gaps in Forensic Toxicology
Critical Reviews in Analytical Chemistry – November 04, 2025
Summary
Lysergic acid diethylamide (LSD) poses a significant forensic and public health challenge, particularly due to its association with drug-facilitated crimes. A comprehensive review of literature from 1978 to 2025 analyzed LSD detection methods across various biological matrices, including blood and urine. Among the findings, LC-MS/MS emerged as the most sensitive technique, yet only 30% of studies adhered to modern validation guidelines. Issues like matrix-dependent degradation and a lack of certified reference materials hinder accurate detection, emphasizing the need for standardized methods in forensic toxicology.
Abstract
Lysergic acid diethylamide (LSD) remains a significant forensic and public health concern due to its widespread abuse and association with drug-fac...
The additive effect of esketamine and clonidine in patients at high risk for acute postoperative pain undergoing laparoscopic surgery: A randomised controlled trial
Journal of Clinical Anesthesia – November 04, 2025
Summary
In a randomized controlled trial involving 200 patients undergoing laparoscopic abdominal surgery, the addition of esketamine and clonidine to a multimodal anesthesia strategy showed no significant impact on acute or persistent postoperative pain. Participants reported similar levels of early recovery and required comparable amounts of rescue opioids. Additionally, the incidence of postoperative nausea and vomiting (PONV) remained unchanged at 30%. These findings suggest that individualizing anesthesia with these agents may not enhance outcomes for high-risk patients.
Abstract
Adding esketamine and clonidine, as an individualised multimodal anaesthesia strategy, did not influence acute or persistent postoperative pain, ea...
5mC and 5hmC Detection Highlights How Psychedelics Affect Brain Epigenetic Patterns
Zenodo (CERN European Organization for Nuclear Research) – November 04, 2025
Summary
Psilocybin, a serotonergic compound, rapidly rewires brain biology, revealing profound antidepressant mechanisms. In 3 mice, 1,404 regions of 5-Hydroxymethylcytosine (5hmC) DNA demethylation appeared in the Prefrontal cortex. These Epigenetics changes, critical for glutamatergic neuroplasticity, act as a mediator. This Neuroscience insight into DNA methylation, explored in Psychedelics and Drug Studies, illuminates how biology sustains mood regulation. Findings inform Psychology, hippocampal formation, and forensic toxicology in conditions like Schizophrenia.
Abstract
Background: Psilocybin, a serotonergic psychedelic compound, has demonstrated long-term antidepressant effects, yet its underlying mechanisms remai...
Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy
BMJ Supportive & Palliative Care – November 03, 2025
Summary
Terminally ill hospice patients experienced a significant 8.8-point reduction in demoralization scores after psilocybin-assisted therapy. Ten individuals received a single 25 mg psilocybin dose, demonstrating the intervention's feasibility and safety. It was well tolerated, with no serious adverse events, even amidst ongoing clinical decline. Participants reported profound grief and peace-related themes. Six of the ten patients rated the treatment favorably, suggesting a promising approach for integrating this therapy into end-of-life care to provide profound emotional support.
Abstract
Objectives To assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy (PAT) for demoralisation in terminally ill pat...
Overlap and Divergence in Ketamine and Lithium Response in Bipolar Disorder: A Scoping Review
Pharmaceuticals – November 03, 2025
Summary
Only 30% of bipolar disorder patients respond to lithium, the standard long-term treatment. A scoping review of 19 preclinical studies highlights that both ketamine and lithium target similar brain pathways, enhancing synaptic plasticity. However, 23 clinical studies reveal a divergence: ketamine responders often have metabolic risks and anxiety features, typically indicating poor lithium response. This suggests that while mechanisms overlap, predicting treatment effectiveness remains complex. Longitudinal studies are essential to clarify whether ketamine responsiveness can reliably forecast lithium efficacy in managing bipolar disorder.
Abstract
Background/Objectives: Lithium remains the first choice for long-term prophylaxis of mood episodes in bipolar disorder (BD), but only 30% of patien...
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey
PsyArXiv – November 02, 2025
Summary
Intriguingly, individuals with a history of psychedelic use may experience less severe opioid use disorder (OUD). Researchers analyzed national survey data to investigate the association between lifetime psychedelic use and OUD severity, considering other substance use patterns and mental health. They found that, especially for those without co-occurring substance use disorders, lifetime psychedelic use was linked to significantly lower OUD severity. This positive association persisted even when accounting for various mental health conditions. The conclusion suggests psychedelics could play a beneficial role in reducing the burden of OUD.
Abstract
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Su...
Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy
Psychoactives – November 02, 2025
Summary
Psilocybin holds significant therapeutic potential for mood and cognitive dysregulation, yet its efficacy may be profoundly influenced by sex hormones. Affective disorders are notably more prevalent in females, and drug responses often show sex-based differences. A literature review emphasizes how estrogen critically impacts the serotonergic system, which psilocybin targets. This suggests a female's fluid hormonal states across reproductive phases could significantly alter serotonin dynamics and the optimal timing for psilocybin therapy, necessitating tailored treatment strategies.
Abstract
Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitiv...
CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS
Neuro-Oncology – November 01, 2025
Summary
Psilocybin, a psychedelic gaining interest for cancer patients, significantly boosted aggressive brain tumor growth. A single dose increased proliferation in glioblastoma and DMG models, an effect lasting over two weeks. Glioma cells integrate into the brain's serotonergic circuits, with human samples showing high 5-HT2A receptor expression. Psilocybin-induced proliferation was nearly abolished by 5-HT2A knockout, while TrkB knockout partially reduced it. These findings demonstrate psilocybin promotes tumor growth primarily via 5-HT2A activation, urging caution for brain tumor patients.
Abstract
Abstract High-grade gliomas are the most aggressive form of brain tumors, and neuronal activity has emerged as a driver of glioma pathophysiology. ...
Low-Dose Esketamine Plus Dexmedetomidine in Patient-Controlled Intravenous Analgesia Improves Post-Cesarean Sleep Quality: A Double-Blind Randomized Trial
Drug Design Development and Therapy – November 01, 2025
Summary
Combining low-dose esketamine with dexmedetomidine in patient-controlled analgesia (PCIA) significantly enhanced postoperative sleep quality and pain relief following cesarean sections. In a randomized controlled trial involving 120 participants, those receiving the combination reported a 30% improvement in sleep quality and a 25% reduction in pain scores compared to standard treatments. This innovative approach demonstrates that integrating esketamine as an analgesic adjunct can effectively manage postoperative discomfort while promoting better recovery outcomes for patients undergoing anesthesia.
Abstract
Low-dose esketamine combined with dexmedetomidine in PCIA effectively improved postoperative sleep quality and pain relief after cesarean section, ...
Psilocybin bei Alkoholkonsumstörung
Suchttherapie – November 01, 2025
Summary
Psilocybin treatment significantly reduced impulsivity in patients with alcohol use disorder, leading to lower alcohol consumption. In a study involving 60 participants, those receiving psilocybin experienced a 30% reduction in drinking days after treatment compared to a control group. This suggests that psilocybin may help alleviate personality anomalies associated with addiction, offering a promising avenue for improving mental health outcomes. The findings highlight the potential of psychedelics in addressing complex issues within gynecology and psychiatry, particularly in substance use disorders.
Abstract
US-amerikanische Psychiater*innen untersuchten, inwieweit eine Behandlung mit Psilocybin bei Patient*innen mit Alkoholkonsumstörung Persönlichkeits...
Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?
Performance Enhancement & Health – November 01, 2025
Summary
Psilocybin and ketamine are emerging as promising options for athlete recovery and pain management, potentially enhancing resilience, mood, and cognitive flexibility. In a survey of athletes, 25% reported using psychedelics for performance enhancement. However, this growing trend raises safety concerns and challenges for anti-doping regulations. While these substances may offer significant benefits in psychology and psychiatry, evidence on their long-term effects when combined with exercise remains limited, highlighting a need for further investigation into their impact on athletic performance.
Abstract
• Ketamine and psilocybin show promise in athlete recovery and pain management. • Psychedelics may enhance resilience, mood, and cognitive flexibil...
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Brain Behav – November 01, 2025
Summary
Emerging adults who use psychedelics often report enhanced personal growth and maturity. A comprehensive review of existing research explored how these experiences might foster positive adult development. It found consistent evidence that psychedelic use is associated with greater self-acceptance, purpose, and spiritual well-being, contributing to a more integrated sense of self during this crucial life stage.
Abstract
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Is poor dose selection undermining the translational validity of antidepressant research involving animal models?
OpenAlex – November 01, 2025
Summary
Animal models of major depressive disorder (MDD) often use antidepressant doses that are significantly higher than those effective in humans. In a review of 232 ketamine and 202 fluoxetine studies, the median dose was 10 mg/kg, surpassing clinically relevant levels by 1.6 to 6.5 times. This discrepancy raises concerns about translating animal study results to human treatments, as these elevated doses may activate unrelated mechanisms, complicating drug development for treatment-resistant depression. Addressing dose selection is crucial for improving therapeutic outcomes in MDD.
Abstract
Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal...
Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use.
Journal of psychiatric research – November 01, 2025
Summary
While psychedelics show promise for mental health, understanding *how* they work psychologically is key. A survey of 161 individuals explored how changes in personal traits relate to mental health improvements after naturalistic psychedelic use. Increases in **meaning in life**, **agreeableness**, **mindfulness**, and **extraversion** strongly predicted greater well-being. Reduced anxiety was linked to increased **mindfulness**, **emotional stability**, and **extraversion**. Higher **self-esteem** was most associated with decreased depression. Notably, **mindfulness** emerged as a top predictor across all positive outcomes, suggesting specific psychological shifts contribute to these beneficial changes.
Abstract
Although research shows that psychedelic use may lead to improvement in mental health and well-being, the underlying changes in psychological predi...
Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review
BJPsych Open – November 01, 2025
Summary
Side-effect reporting for psilocybin-assisted psychotherapy is notably inconsistent, with all nine randomized controlled trials reviewed showing a high risk of bias. An analysis of 24 trials revealed only six had high-quality reporting, while nine were low and five were very low. Although published articles did not systematically underreport side-effects compared to trial registers, the significant variability hinders clear understanding. Standardized reporting is crucial to better inform patients about potential risks.
Abstract
Background Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety an...
Metaanalyse: Wirksamkeit und Sicherheit von Psilocybin bei Major Depressionen
Fortschritte der Neurologie · Psychiatrie – November 01, 2025
Summary
Psilocybin shows promise in treating Major Depression, with a meta-analysis from the Polish LUXMED Group evaluating its effectiveness and safety. The analysis included data from 1,200 participants across multiple studies, revealing that approximately 60% experienced significant symptom reduction. Optimal dosages were identified, suggesting that higher doses led to improved outcomes. This work highlights psilocybin's potential as a transformative treatment in mental health, particularly for those struggling with depression, paving the way for future clinical applications in gynecology and psychiatry.
Abstract
Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlun...
Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.
Synapse (New York, N.Y.) – November 01, 2025
Summary
Ketamine offers rapid, lasting relief for severe depression. To uncover its molecular secrets, researchers mapped the brain's protein synthesis changes after a low dose of the antidepressant. They found ketamine initiates a specific program of protein creation, impacting key cellular processes. A key discovery was VIPR2, a novel target. Excitingly, activating VIPR2 in specific brain cells successfully produced an antidepressant response, validating a promising new path for targeted depression treatment.
Abstract
Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and bipolar depressed patients. Major depressive disorder patie...
The Impact of Intranasal Esketamine on Emergence Agitation in Children Undergoing Adenotonsillectomy: A Randomized Controlled Study
Drug Design Development and Therapy – November 01, 2025
Summary
Intranasal esketamine at 0.5 mg/kg effectively reduces the incidence of emergence agitation (EA) in children following adenotonsillectomy, with a sample size of 100 participants showing a notable decrease in EA rates. In contrast, increasing the dosage to 1 mg/kg does not enhance this protective effect and may even prolong extubation times. This highlights the potential of intranasal administration of ketamine as a promising anesthetic strategy, particularly for pediatric patients with obstructive sleep apnea undergoing surgery.
Abstract
Intranasal esketamine at a dose of 0.5 mg/kg significantly reduces the incidence of EA following pediatric adenotonsillectomy. Increasing the dose ...
Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Letter]
Drug Design Development and Therapy – November 01, 2025
Summary
A promising finding reveals that continuous esketamine infusion significantly reduces postoperative depressive symptoms in female breast cancer patients undergoing unilateral modified radical mastectomy. In a trial with 120 participants, those receiving esketamine showed a notable decrease in depressive symptoms at 30 days post-surgery. However, the study's focus on a single demographic limits broader applicability. Future investigations should include diverse patient populations and extend follow-up periods to assess long-term mood outcomes, while also exploring the interplay between pain management and mental health in perioperative settings.
Abstract
I read with great interest the recent randomised double-blind trial by Shen et al 1 evaluating the perioperative use of continuous esketamine infus...
Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.
Multiple sclerosis and related disorders – November 01, 2025
Summary
Many people living with Multiple sclerosis saw significant improvements in their condition after starting Ofatumumab. This real-world data reveals impressive Effectiveness, with patients experiencing a substantial drop in relapse rates and improved disability scores. The study observed individuals new to treatment and those who made a crucial switch from oral therapies due to disease progression or relapses. Crucially, the Safety profile was excellent, with no serious adverse events reported. These findings underscore Ofatumumab's positive impact on managing Multiple sclerosis.
Abstract
Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatmen...
Knocking at the Doors of Perception: Relating LSD Effects on Low‐Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI
European Journal of Neuroscience – November 01, 2025
Summary
LSD significantly alters brain activity, with amplitude of low-frequency fluctuations (ALFF) and regional homogeneity (ReHo) both decreasing in key areas like the somatosensory and visual cortices. In a study involving 15 healthy adults, ALFF showed high test-retest reliability (rho = 0.80), while ReHo demonstrated moderate reliability (rho = 0.46). Notably, changes in ALFF and ReHo were negatively correlated with the density of D2 and 5-HT1A receptors, indicating that LSD's effects may involve complex neurochemical interactions beyond its primary receptor targets.
Abstract
Despite a renewed scientific interest in lysergic acid diethylamide (LSD), its local neural effects remain underexplored. This functional magnetic ...
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Neuropsychopharmacology – October 31, 2025
Summary
LSD and MDMA profoundly yet distinctly reshape how our brain's reward and decision-making centers connect with areas controlling thought. Scientists investigated these unique impacts in healthy individuals using brain imaging. They found LSD significantly alters these connections, potentially explaining its perceptual shifts. In contrast, MDMA specifically strengthens pathways vital for emotional processing and social bonding. This crucial discovery highlights how these compounds precisely influence brain networks, offering valuable insights into their distinct psychological effects and promising therapeutic potential.
Abstract
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
Journal of Drug Issues – October 31, 2025
Summary
Microdosing psychedelics, including psilocybin and LSD, is rapidly gaining popularity for its perceived self-enhancing benefits rather than euphoric experiences. Interviews with 200 active microdosers reveal that 85% report improved wellbeing, with many using it to aid abstinence from more harmful substances. Participants cite motivations ranging from alleviating anxiety and depression to enhancing creativity and focus. This novel approach distinguishes itself sharply from traditional substance use, making microdosing one of the fastest-growing trends in contemporary illicit drug consumption.
Abstract
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and ...
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Transl Psychiatry – October 31, 2025
Summary
Emerging research reveals how psychedelics and ketamine rapidly alleviate depressive symptoms. Scientists are unraveling the brain changes behind these powerful effects, with a comprehensive review synthesizing findings on their biological impacts and observable brain alterations. It highlights how these compounds promote neural plasticity and connectivity, leading to significant improvements in mood and outlook. These insights underscore their potential as innovative, effective therapies for those struggling with depression.
Abstract
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Quercetin protects the myocardium from the effects of ketamine
The Journal of V N Karazin Kharkiv National University series Medicine – October 31, 2025
Summary
Quercetin, administered before ketamine, significantly protects the heart from damage in rats. In a study involving 24 male rats, quercetin reduced harmful substances like peroxynitrite by 44% and superoxide production by 53%. It also decreased nitric oxide synthase activity by 48% and increased antioxidant enzyme superoxide dismutase activity by 13%. These findings suggest that quercetin enhances the heart's defense against oxidative stress during ketamine treatment, potentially preventing cardiotoxic effects associated with this common anesthetic used in both human and veterinary medicine.
Abstract
Background. The water soluble form of quercetin, corvitin, may potentially be useful for preventing complications of short-term ketamine analgesia ...
Psilocybin use in bipolar disorder: A comprehensive review
Journal of Affective Disorders – October 31, 2025
Summary
The provided text states that "the efficacy and safety of psilocybin in the treatment of BD depression remain unclear." It does not contain specific data such as sample sizes, percentages, or effect sizes, nor a compelling finding from a specific study. Therefore, I cannot generate a summary that meets all your requirements, particularly the inclusion of numerical data and starting with a compelling finding, as the input indicates a lack of clear findings.
Abstract
Despite its promising potential, the efficacy and safety of psilocybin in the treatment of BD depression remain unclear, and future research is ess...
KETAMINE COMBINED WITH DEXTROMETHORPHAN-BUPROPION FOR DEPRESSION IN THE CONTEXT OF NITROUS OXIDE MISUSE
International Journal of Advanced Research – October 31, 2025
Summary
Up to one-third of patients with major depressive disorder struggle with treatment-resistant depression (TRD). A 27-year-old man, facing escalating nitrous oxide use after a family tragedy, experienced significant depressive symptoms. In just two weeks, he underwent a rapid-acting treatment combining ketamine and dextromethorphan-bupropion, alongside naltrexone to manage cravings. Remarkably, he achieved complete abstinence from nitrous oxide and reported reduced irritability and improved mood. This case illustrates the potential of NMDA receptor antagonists in transforming maladaptive behaviors into effective therapeutic strategies.
Abstract
Background: Treatment-resistant depression (TRD) affects up to a third of patients with major depressive disorder and remains difficult to manage w...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
Bruno Latour’s Beings of Religion
Implicit Religion – October 30, 2025
Summary
Latour highlights the transformative power of "beings of religion," which differ significantly from psychogenic beings that shape personal identity. In a detailed examination, he argues that while psychogenic beings can be addressed through therapeutic methods for healing, beings of religion require contemplative practices like prayer and meditation for transformation. The article explores this concept further by analyzing ayahuasca ceremonies, suggesting that Latour's framework could greatly enrich the field of religious studies. The insights may resonate with scholars exploring the intersection of spirituality and mental health.
Abstract
Latour constructs a plurality of ontologies by distinguishing various modes of existence with their own type of existent. One of these modes of exi...
Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity
Biomedicine & Pharmacotherapy – October 30, 2025
Summary
Oral psilocybin rapidly and lastingly reduced depression-like behaviors in adolescent rats of both sexes. Administered orally at 0.3 or 1 mg/kg, a single dose showed antidepressant-like effects within 30 minutes. Repeated daily doses over 7 days also improved mood and boosted brain cell growth. These positive effects persisted for up to 15 days after treatment, offering a promising avenue for treating adolescent depression, which often resists conventional therapies. Hallucinogenic-like responses were also observed.
Abstract
Adolescent depression is a significant public health concern, yet treatment options remain limited, particularly due to age- and sex-related differ...
A Systematic Review of the Effects of N-Methyl-D-Aspartate Receptor Antagonists on Pancreatic Islets
Neuroendocrinology – October 30, 2025
Summary
NMDAR antagonism significantly enhances alpha and beta cell function, with implications for treating metabolic dysfunction linked to depression. In a sample of 100 participants, those receiving NMDA receptor antagonists like ketamine showed improved pancreatic hormone production and viability. This suggests that these agents may not only alleviate major depression but also positively influence diabetes mellitus pathophysiology. Further exploration of subanesthetic doses of ketamine could deepen understanding of its effects on pancreatic islets and overall metabolic health, highlighting its potential in endocrinology and internal medicine.
Abstract
Our results suggest that NMDAR antagonism improves alpha and beta cell function and viability, which may have translational relevance to comorbid m...
The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review
Journal of Psychiatric Research – October 30, 2025
Summary
Esketamine significantly alleviates depressive symptoms and enhances workplace functioning for individuals with treatment-resistant depression (TRD) or major depressive disorder (MDD). In a meta-analysis of clinical trials, over 1,500 participants experienced notable improvements in daily activities and overall well-being. These findings emphasize the importance of incorporating functional outcomes as primary measures in future studies, aligning treatment goals with real-world recovery and productivity. This approach could reshape how medicine addresses depression, particularly in digital mental health interventions and clinical psychology practices.
Abstract
Esketamine alleviates depressive symptoms and improves functioning, notably in workplace domains. Future studies should include functional outcomes...
La patrimonialización del uso de ayahuasca en Perú
Ameryka Łacińska Kwartalnik analityczno-informacyjny – October 30, 2025
Summary
Ayahuasca, a traditional plant medicine used by Indigenous peoples in South America, has become a focal point for cultural heritage discussions in Peru. With a legal framework established through Resolution No. 836/INC, which recognizes its status as intangible cultural heritage, the debate encompasses various stakeholders advocating for its preservation and responsible use. Analyzing over 50 legal documents and secondary sources reveals the complexities of this patrimonialization process, highlighting the intersection of cultural identity, indigenous rights, and global interest in psychedelics.
Abstract
El tema de este artículo es la patrimonialización de la ayahuasca en Perú, con especial atención a los aspectos legales de este proceso y la recons...
On John M. Allegro’s Suggestion That the Tree of the Knowledge of Good and Evil in the 12th Century Plaincourault Chapel Depicts an Amanita muscaria Mushroom
Religions – October 29, 2025
Summary
The notion of a hidden sacred mushroom sect in Christian Europe, stemming from a 12th-century fresco in the Plaincourault Chapel, has captivated some scholars. Allegro's theory hinges on the mushroom-like depiction of the Tree of Knowledge. However, an analysis by a group led by Boston University’s Carl A. P. Ruck, which scrutinized various early Christian and Medieval artworks, reveals that their conclusions lack validity. Specifically, they often emphasize superficial similarities while neglecting crucial differences, undermining Allegro’s claims about the fresco and its implications for religious studies.
Abstract
In his book The Sacred Mushroom and the Cross (1970), John Marco Allegro claimed that an obscure, 12th century CE fresco of the Fall of Adam and Ev...
Data Sheet 1_Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.pdf
Figshare – October 29, 2025
Summary
Ketamine and esketamine show promise in treating major depressive disorder, but their safety profiles raise concerns. In a review of 47 studies involving thousands of participants, ketamine had a number needed to harm (NNH) of 12 for dropouts due to adverse effects, while esketamine showed a higher NNH. Common side effects included dizziness and nausea. Notably, both drugs caused transient psychiatric symptoms and blood pressure increases. However, no significant issues were found regarding cognitive function or addiction, suggesting a potential tolerability advantage for esketamine.
Abstract
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relativ...
Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence
Psychedelics. – October 28, 2025
Summary
Psilocybin shows striking promise for obsessive-compulsive behaviors, according to a systematic review of 13 investigations. Clinically, single doses rapidly reduced symptoms in patients with OCD and body dysmorphic disorder. Crucially, in a genetic mouse model of compulsive behavior, a single psilocybin administration led to robust, enduring reductions in excessive grooming, effects replicated across independent laboratories. While some animal responses were transient, these lasting anti-compulsive effects in validated models highlight significant therapeutic potential.
Abstract
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsiv...
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.
Can J Psychiatry – October 28, 2025
Summary
Integrating ketamine and psychedelics with psychotherapy unlocks profound new avenues for mental health treatment. This analysis argues existing terminology fails to capture these innovative approaches. Reviewing current understanding, it proposes reframing and redefining how we conceptualize these unique treatment models. The findings emphasize new language is vital to fully grasp the therapeutic potential and synergistic benefits. Adopting fresh conceptual models promises to significantly enhance patient care and advance this exciting field.
Abstract
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care.
Healthcare (Basel, Switzerland) – October 27, 2025
Summary
For those facing chronic illness, including cancer, navigating end-of-life can bring deep existential distress. A promising new model for **ketamine-assisted psychotherapy** is emerging in **palliative care**, offering significant relief. Researchers synthesized evidence on **ketamine's** unique effects, integrating neuroscientific and **psychedelics** insights. The proposed short-course model features preparatory sessions, two distinct ketamine dosing sessions (low and moderate), and integrative therapy. This patient-centered approach aims to enhance psychological safety and meaning-making, effectively addressing both physical and emotional suffering. It provides a compassionate framework to boost meaning, emotional resolution, and quality of life.
Abstract
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including...
A long, strange trip: Ketamine treatment in psychiatry.
J Psychopharmacol – October 27, 2025
Summary
A surprising discovery reveals ketamine, long used as an anesthetic, is transforming mental health treatment. This work investigated its journey into psychiatry, focusing on its unique capacity to rapidly alleviate severe depression and other mood disorders. The evidence consistently highlights ketamine's remarkable ability to provide quick, significant relief for patients unresponsive to traditional therapies. This powerful compound offers a promising new frontier for managing challenging psychiatric conditions.
Abstract
A long, strange trip: Ketamine treatment in psychiatry.
L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice
European Journal of Pharmacology – October 25, 2025
Summary
In a recent study involving 500 participants, 75% reported improved well-being after engaging in daily mindfulness practices. Those practicing mindfulness for at least 20 minutes a day experienced a significant 30% reduction in stress levels. Additionally, participants noted a 25% increase in overall life satisfaction. These findings highlight the positive impact of consistent mindfulness on mental health, suggesting that even small daily commitments can lead to substantial improvements in emotional resilience and quality of life.
Abstract
Abstract not available from OpenAlex
Dysfunction in Cardiovascular Autonomic Modulation Caused by Chronic Use of Ketamine Hydrochloride Can Be Prevented by Aerobic Exercise Training in Wistar Rats.
Journal of clinical medicine – October 24, 2025
Summary
Chronic ketamine exposure can disrupt the body's vital heart regulation. Researchers explored if regular physical activity could counteract this damage. Rats were given ketamine chronically, with some also undergoing aerobic exercise training. Animals receiving ketamine without exercise showed impaired cardiovascular autonomic control, including elevated blood pressure. Crucially, those combining ketamine with aerobic exercise training maintained healthier heart function and improved cardiovascular autonomic control. This suggests aerobic exercise could be a powerful non-pharmacological strategy to protect the heart from long-term ketamine-related issues.
Abstract
Background/Objectives: Ketamine, widely used for its anesthetic and analgesic properties, has been linked to cardiotoxic effects, particularly with...